Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
10.78
-0.06 (-0.55%)
Apr 24, 2025, 4:08 PM HKT
-3.75%
Market Cap 64.27B
Revenue (ttm) 292.91B
Net Income (ttm) 4.84B
Shares Out n/a
EPS (ttm) 1.31
PE Ratio 13.27
Forward PE n/a
Dividend 0.53 (4.88%)
Ex-Dividend Date Sep 17, 2024
Volume 5,116,929
Average Volume 5,625,403
Open 10.88
Previous Close 10.84
Day's Range 10.70 - 10.88
52-Week Range 10.04 - 14.70
Beta 0.40
RSI 40.96
Earnings Date Mar 28, 2025

About HKG:2607

Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, syste... [Read more]

Sector Healthcare
Founded 1994
Employees 49,402
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2607
Full Company Profile

Financial Performance

In 2024, HKG:2607's revenue was 275.25 billion, an increase of 5.75% compared to the previous year's 260.30 billion. Earnings were 4.55 billion, an increase of 20.82%.

Financial numbers in CNY Financial Statements

News

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...

4 months ago - Benzinga